AbbVie drops lawsuit

AbbVie's (ABBV +0.4%) spat with Europe's drug regulator ends with the agency's acceptance of redacted documents pertaining to the company's rheumatoid arthritis drug.

Last year, the firm sought an injunction to block the medicines regulator from releasing confidential and commercially-sensitive information about the drug.

Researchers want access to the raw data as a means to improve third-party scrutiny of new drugs. Unsurprisingly, companies oppose this citing potential damage to their businesses and increased difficulty defending patents.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs